Internal Medicine, Hematology & Oncology · Lorain, OH
NPI
1548263163
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3600 Kolbe Rd Ste 105
Lorain, OH, 44053
Phone (440) 324-0400
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.9M
109,622 services
Medicare patients, 2024
444
Average age 75
Drug cost, 2024
$5.5M
1,499 prescriptions
Company payments, 2025
$124K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kasra Karamlou was code J0897 (injection, denosumab, 1 mg), 2,340 times for 13 patients. In total Kasra Karamlou billed 109,622 services in 125 codes, and Medicare paid $1.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-06-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 2,340 | 13 | $19.92 | $47K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,326 | 33 | $0.09 | $120 |
| 99214 Office E&M - Established | Office | 709 | 275 | $80.52 | $57K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 680 | 23 | $0.76 | $518 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 576 | 15 | $0.08 | $44.4 |
| 96375 Injection Administration | Office | 324 | 42 | $10.98 | $3,559 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 270 | 144 | $12.44 | $3,360 |
| 96413 Chemotherapy Administration | Office | 243 | 53 | $89.09 | $22K |
| 96401 Chemotherapy Administration | Office | 154 | 15 | $50.05 | $7,707 |
| J3490 Unclassified drugs | Office | 74 | 14 | $0.31 | $23.04 |
| 96372 Injection Administration | Office | 74 | 37 | $9.72 | $720 |
| 36415 Venipuncture Blood Collection | Office | 70 | 57 | $8.43 | $590 |
| 96417 Chemotherapy Administration | Office | 68 | 17 | $44.81 | $3,047 |
| 96415 Chemotherapy Administration | Office | 68 | 19 | $19.52 | $1,328 |
| 96367 Intravenous Infusion, Hydration | Office | 59 | 22 | $19.51 | $1,151 |
By year: 2022 $4.4M for 193,301 services; 2023 $4.0M for 175,583 services; 2024 $1.9M for 109,622 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 70 | 57 | $8.43 | $590 |
Medicare prescription drug claims, 2024
In 2024, the drug Kasra Karamlou prescribed most often to Medicare patients was Prednisone, with 95 prescriptions and refills. In total Kasra Karamlou wrote 1,499 Medicare prescriptions that cost $5.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 95 | 109 | 35 | $424 |
| Anastrozole Generic | 67 | 169 | 28 | $996 |
| Ondansetron Hcl Generic | 64 | 64 | 43 | $2,030 |
| Prochlorperazine Maleate Generic | 57 | 57 | 41 | $1,335 |
| Eliquis Apixaban | 51 | 77 | 18 | $44K |
| Brukinsa Zanubrutinib | 47 | 49 | Under 11 | $690K |
| Hydroxyurea Generic | 43 | 76 | 12 | $588 |
| Gabapentin Generic | 42 | 80 | 19 | $637 |
| Jakafi Ruxolitinib Phosphate | 41 | 41 | Under 11 | $576K |
| Acyclovir Generic | 40 | 88 | 16 | $835 |
| Dexamethasone Generic | 28 | 36 | 18 | $323 |
| Abiraterone Acetate Generic | 27 | 31 | Under 11 | $41K |
| Pomalyst Pomalidomide | 27 | 27 | Under 11 | $577K |
| Oxycodone Hcl Generic | 26 | 26 | Under 11 | $481 |
| Revlimid Lenalidomide | 25 | 25 | Under 11 | $430K |
Brand drugs: 373 claims; generic drugs: 1,126 claims; opioid claims: 88.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kasra Karamlou $124K ($124K in general payments such as food, travel and fees) from 16 companies. The largest payer was BeOne Medicines USA, Inc. with $28K.
| Company | Payments | Amount |
|---|---|---|
| BeOne Medicines USA, Inc. ONC | 14 | $28K |
| Incyte Corporation INCY | 16 | $22K |
| GlaxoSmithKline, LLC. GSK | 10 | $18K |
| Abbvie Inc. ABBV | 7 | $13K |
| Sobi, Inc SOBI.ST | 6 | $12K |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $9,374 |
| Genzyme Corporation SNY | 4 | $8,112 |
| Stemline Therapeutics Inc. | 4 | $6,409 |
| Karyopharm Therapeutics Inc. KPTI | 3 | $4,988 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $1,838 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.